A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2004
11/18/2004	US20040229339 Comprises neisseria membrane protein for use as tool in generation of vaccine to prevent infection and sepsis in infants
11/18/2004	US20040229338 Using transgenic and attenuated salmonella comprising tumor modulatory proteins and pharmceutical conjugate to treat cell proliferative disorders; targeted tissue therapy
11/18/2004	US20040229266 RNA interference mediating small RNA molecules
11/18/2004	US20040229260 Comprises nucleotide sequences coding interleukin-1b converting enzyme ligand for use in diagnosis, prevention and treatment of autoimmune, connective tissue and crohn's diseases
11/18/2004	US20040229232 Compositions and methods for the diagnosis and treatment of tumor
11/18/2004	US20040228936 Administering cocoa extracts including procyanidin monomers and oligomers to treat inflammation, atherosclerosis, and cardiovascular disorders; bactericides, foods; cyclooxygenase and/or lipoxygenase inhibitors
11/18/2004	US20040228935 Plant extract comprising steroidal glycosides from the genus Trichocaulon or Hoodia produced by solvent extraction
11/18/2004	US20040228930 Administering carbon monoxide to reduce tissue damage
11/18/2004	US20040228924 Pharmaceutical products
11/18/2004	US20040228911 Vinorelbine compositions and methods of use
11/18/2004	US20040228905 Anti-inflammatory and antimicrobial uses for bioactive glass compositions
11/18/2004	US20040228898 Thermopolymer composition and related methods
11/18/2004	US20040228884 Ion-pair delivery system for cosmetic and pharmaceutical compositions
11/18/2004	US20040228881 Compositions and methods for modulating neural sprouting
11/18/2004	US20040228880 Vaccine composition comprising iron phosphate as vaccine adjuvant
11/18/2004	US20040228872 such as genistein adminstered to sustain release of toxin
11/18/2004	US20040228869 Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
11/18/2004	US20040228868 induces apoptosis in mammalian cancer cells; irinotecan; kits
11/18/2004	US20040228855 Method for treating symptoms of diabetes
11/18/2004	US20040228807 Condensation aerosol for delivery of a drug selected from the group consisting of zaleplon, zolpidem and zopiclone
11/18/2004	US20040228805 Synergistic effect for treating respiratory disorders; a capsule containing inhalable powder for asthma or COPD; active 3-oxa-9-azatricyclo(3,3,1,0(2,4))nonane ring compound
11/18/2004	DE4124409B4 Pharmazeutische Zubereitungen Pharmaceutical preparations
11/18/2004	DE10319399A1 Kosmetische und/oder pharmazeutische Zubereitungen Cosmetic and / or pharmaceutical preparations
11/18/2004	DE10318714A1 Wirkstoff-Kombination und Therapien zur Bekämpfung des Alkoholmissbrauchs Drug combination therapies to combat alcohol abuse
11/18/2004	DE10297331T5 Behandlung und Diagnose von Insulin-resistenten Zuständen Treatment and diagnosis of insulin-resistant conditions
11/18/2004	CA2525225A1 A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
11/18/2004	CA2524891A1 Ultraviolet-shielding type patch
11/18/2004	CA2524610A1 Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
11/18/2004	CA2524603A1 Controlled release composition containing a strontium salt
11/18/2004	CA2524368A1 Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
11/18/2004	CA2524217A1 Compositions for inducing immune responses
11/18/2004	CA2524172A1 Cngh0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses
11/18/2004	CA2524025A1 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
11/18/2004	CA2523242A1 Ginkgo biloba extract as a treatment for therapeutic induced neurotoxicity
11/18/2004	CA2519930A1 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use
11/18/2004	CA2518076A1 Medicinal compositions for concomitant use as anticancer agent
11/17/2004	EP1477180A1 Inhibitors of proteasomal activity for stimulating bone and hair growth
11/17/2004	EP1477178A2 Health supplements containing phyto-oestrogens, analogues or metabolites thereof
11/17/2004	EP1477168A1 Use of cabergoline in the treatment of restless leg syndrome
11/17/2004	EP1477166A1 The use of riluzol combined with excipients and additives for the treatment of disorders characterised by hyperproliferation of keratinocytes, in particular neurodermitis and psoriasis
11/17/2004	EP1477165A2 Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
11/17/2004	EP1477163A1 New film coating
11/17/2004	EP1477162A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose
11/17/2004	EP1476746A2 Method for discovering pharmacologically active substances
11/17/2004	EP1476545A2 Aggrecanase molecules
11/17/2004	EP1476543A1 Viral variants with altered susceptibility to nucleoside analogs and uses thereof
11/17/2004	EP1476470A1 Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments
11/17/2004	EP1476460A2 A nucleic acid encoding a g-protein-coupled receptor; and uses thereof
11/17/2004	EP1476456A2 Compositions and methods for surrogate antibody modulation of an immune response and transport
11/17/2004	EP1476425A2 Heterocyclic arylsulfonamidobenzylic compounds
11/17/2004	EP1476423A2 Arylsulfonamidobenzylic compounds
11/17/2004	EP1476200A2 Compositions and method for regulation of calcium-dependent signalling in brain
11/17/2004	EP1476199A2 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
11/17/2004	EP1476195A2 Enhancement of the action of central and peripheral nervous system agents
11/17/2004	EP1476193A1 A weight management system for obese animals
11/17/2004	EP1476192A1 Methods and compositions for treating hyperproliferative conditions
11/17/2004	EP1476187A2 Methods of extending corneal graft survival
11/17/2004	EP1476186A1 Use of an inhibitor or antagonist against tissue factor
11/17/2004	EP1476181A2 Polyalkylene polymer compounds and uses thereof
11/17/2004	EP1476180A2 Interleukin-2 mutants with reduced toxicity
11/17/2004	EP1476171A2 Transportation of nucleic acid substances
11/17/2004	EP1476169A1 Methods of inhibiting orthopoxvirus replication with nucleoside compounds
11/17/2004	EP1476168A2 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
11/17/2004	EP1476158A1 Nicotinamide derivatives useful as pde4 inhibitors
11/17/2004	EP1476157A1 Nicotinamide derivatives useful as pde4 inhibitors
11/17/2004	EP1476155A2 Methods and compositions for reducing the development of drug tolerance and/or physical dependence
11/17/2004	EP1476154A2 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
11/17/2004	EP1476153A2 Method of treating and preventing bone loss
11/17/2004	EP1476152A2 Use of melatonin analogues for induction of general anesthesia
11/17/2004	EP1476150A2 Carboxyfullerenes and methods of use thereof
11/17/2004	EP1476148A2 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
11/17/2004	EP1476146A1 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
11/17/2004	EP1476142A1 Compositions for pulmonary administration
11/17/2004	EP1476141A2 Tamper-resistant transdermal opioid delivery devices
11/17/2004	EP1476128A2 Lipase inhibiting composition
11/17/2004	EP1476127A1 Nsaid-containing topical formulations that demonstrate chemopreventive activity
11/17/2004	EP1476115A2 Massage appliance
11/17/2004	EP1476067A2 Novel compositions and methods for cancer
11/17/2004	EP1476018A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
11/17/2004	EP1286990B1 Stolonoxides
11/17/2004	EP1272468B1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
11/17/2004	EP1257261B1 Antiviral pharmaceutical compositions containing iron chelators
11/17/2004	EP1250340B1 Methods and compounds for inhibiting mrp1
11/17/2004	EP1242436B1 Oligosaccharide mixture
11/17/2004	EP1185274B1 Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
11/17/2004	EP1171120A4 Methods for alleviating discomfort of a hot flash and compositions therefor
11/17/2004	EP1168997A4 Vacuum assisted closure system with provision for introduction of agent
11/17/2004	EP1105101B1 Compositions and methods for treating intracellular infections
11/17/2004	EP1037649A4 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
11/17/2004	EP0980255B1 Adhesion prevention and an endoscopic insufflation system therefor
11/17/2004	EP0942732B1 Use of nk-1 receptor antagonists for treating movement disorders
11/17/2004	EP0942731B1 Use of nk-1 receptor antagonists for treating substance use disorders
11/17/2004	EP0933995B1 Method of treating endothelial injury
11/17/2004	EP0731811B1 Chaperonin 10
11/17/2004	EP0679160B1 Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis
11/17/2004	CN1547583A 多环鸟嘌呤磷酸二酯酶v抑制剂 Polycyclic guanine phosphodiesterase inhibitor v
11/17/2004	CN1547486A Antibodies to OPGL
11/17/2004	CN1547483A New use of ARTEMIN, a member of the GDNF ligand family
11/17/2004	CN1547478A Use of fucans in the treatment of adhesions, arthritis and psoriasis
11/17/2004	CN1547477A Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

1 ... 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 ... 1151